Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : OSI Pharmaceuticals, Inc
Femme et Homme Max 99 ans
OSI Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
Evaluate in parallel the efficacy of 2 different Tarceva-containing regimens as first-line therapy measured as the percentage of patients that have progressed at 6 months among stage IIIB/IV NSCLC pat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
OSI Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
To determine the objective response rates in patients with untreated unresectable, locally advanced or metastatic cancer of the biliary tract who are treated with OSI-7904L or 5-FU/LV.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
OSI Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors. Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo
The primary objectives of this study are to assess the efficacy of single agent, oral, once daily, Tarceva (150 mg/day) at increasing the DFS following complete surgical resection with or without adju...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations